For patients living with a rare but disabling neuroimmune condition that currently has no proven preventive therapy, a new comparative dataset offers the most substantive evidence yet for a repurposed drug class. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is distinct from multiple sclerosis and neuromyelitis optica, and the absence of approved preventive agents leaves clinicians navigating off-label choices with minimal data to guide them.
This international retrospective cohort study, spanning 2015 through 2025 across eight countries in North and South America, enrolled 116 MOGAD patients — 89% with relapsing disease — who received at least one dose of an interleukin-6 receptor blocker (IL-6RB), predominantly tocilizumab (90%) with a smaller satralizumab cohort (10%). The primary outcome was annualized relapse rate (ARR) during IL-6RB therapy, assessed against a historical IVIG-treated cohort using inverse probability of treatment weighting to control for age, sex, prior relapse burden, and concomitant therapies. The excerpt reports that 60.3% of patients met a key efficacy threshold, with full ARR and time-to-relapse data available in the published article.
The comparative IVIG design is methodologically meaningful: IVIG is among the most commonly used off-label options in MOGAD, making this the first adequately powered head-to-head approximation for these two approaches. IL-6 signaling has well-established roles in B-cell maturation and antibody amplification, providing a plausible mechanistic rationale for targeting this pathway in an antibody-mediated disease. However, several limitations deserve emphasis. The retrospective design precludes causal conclusions, dosing variability in the IVIG cohort introduces noise, and the modest sample size limits subgroup analysis. Notably, satralizumab — a subcutaneous, longer-acting IL-6RB already approved for neuromyelitis optica spectrum disorder — is represented in only 12 patients, an underpowered subset. Still, for a rare disease where randomized trial data remain years away, this multicenter dataset offers clinically actionable signal and will likely influence prescribing practice in the near term.